Cosmos Health Projects Over $3.2 Million in Incremental Annual Revenue from Fort18 in the United States Within 12-18 Months
Rhea-AI Summary
Cosmos Health (NASDAQ:COSM) projects its new nutraceutical Fort18™ will generate over $3.2 million in incremental annual U.S. revenue within 12–18 months, based on current commercialization plans and internal assumptions.
Fort18™, targeting men's sexual stamina and endurance, is expected to launch in June 2026 via a staged rollout starting with e-commerce.
AI-generated analysis. Not financial advice.
Positive
- Projects over $3.2 million in incremental annual U.S. revenue from Fort18™ within 12–18 months
- Fort18™> expands the 18 Series portfolio into the U.S. men's sexual health supplement category
- Staged rollout strategy starting with direct-to-consumer e-commerce and planned retail expansion
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
COSM fell 5.06% with mixed peers: SNYR down 7.68%, ZYXI down 37.34%, YI up 8.42%, EDAP down 1.43%, QIPT flat. Argus momentum shows SNYR and CCM down (median -12.4%) and NSYS up 9.88%, indicating broader sector dynamics alongside stock-specific factors.
Previous Crypto Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 06 | Fort18 U.S. launch | Positive | -0.8% | Announced U.S. launch of Fort18 with positive clinical and dosing details. |
| Apr 30 | Cur18 revenue outlook | Positive | +2.5% | Projected over $2.5M in Cur18 annual U.S. revenue within 12–18 months. |
| Apr 17 | Cur18 U.S. launch plan | Positive | +0.1% | Outlined Q2 Cur18 U.S. launch with enhanced bioavailability data. |
| Apr 13 | Pharmalink order ramp | Positive | +8.5% | Reported third Sky Premium Life order, cumulative 270,000 units toward 3M goal. |
| Apr 10 | Record revenue update | Positive | +3.5% | Disclosed record Q3 2025 revenue and NOOR collagen U.S. growth plans. |
Recent 'crypto'-tag news has generally been positive in tone, with four out of five events seeing the stock trade higher over the next day and one modest negative reaction.
Over the last month, Cosmos has focused on U.S. expansion and branded nutraceuticals. On Apr 10, it reported record 2025 revenue and NOOR U.S. expansion, followed by growing Pharmalink orders on Apr 13. Subsequent releases detailed the 18 Series launch, Cur18 and Liv18 commercialization, and, on May 6, the initial Fort18 introduction. Today’s Fort18 revenue projection extends this commercialization narrative within the same strategic product family.
Historical Comparison
In the past 5 'crypto'-tag updates, COSM averaged a 2.73% next-day move, mostly positive. Today’s Fort18 revenue guidance fits the ongoing U.S. expansion theme.
Same-tag history shows a progression from record revenue and distribution deals to the structured rollout of the 18 Series (NOOR, Cur18, Liv18) and now Fort18 revenue projections in U.S. wellness.
Regulatory & Risk Context
On Apr 24, 2026, Cosmos filed an S-3/A to register 73,523,716 common shares for resale, tied to convertible notes at a $0.176 floor price. The prospectus states selling stockholders, not the company, receive resale proceeds, and outlines a potential increase to a pro forma 126,054,324 shares outstanding if fully converted.
Market Pulse Summary
This announcement outlines Cosmos’s plan for Fort18, targeting over $3.2M in incremental annual U.S. revenue within 12–18 months and a June 2026 launch into a growing sexual health supplement market. It extends the 18 Series strategy of science-based nutraceuticals. In context, investors may track execution of the staged e-commerce and retail rollout, actual sell-through versus projections, and how these efforts interact with the broader capital structure detailed in recent SEC filings.
Key Terms
nutraceutical medical
cagr financial
AI-generated analysis. Not financial advice.
CHICAGO, IL / ACCESS Newswire / May 11, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced it is projecting Fort18™ to generate over
Fort18™ is the latest addition to the Company's "18 Series," a growing portfolio of science-based nutraceutical products. Formulated with a proprietary botanical blend evaluated in published clinical research, Fort18™ enters the U.S. sexual health supplement category targeting men's sexual stamina and endurance. The product is expected to launch commercially in June 2026.
The Company's projection is underpinned by a staged rollout beginning with direct-to-consumer e-commerce, with planned expansion into selected retail channels over time. The forecast incorporates internal assumptions around pricing, anticipated sales volumes, repeat purchase behavior, and distribution growth, and remains subject to the continued execution of the Company's commercialization plans.
According to Grand View Research, the global sexual health supplement market was valued at
Greg Siokas, Chief Executive Officer of Cosmos Health, stated: "Fort18™ marks our entry into the U.S. men's wellness category - a large and rapidly growing market driven by increasing consumer demand for science-supported products. We believe it has the potential to become a meaningful revenue contributor to our nutraceutical portfolio as we scale distribution."
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
No statement made herein has been evaluated by the U.S. Food and Drug Administration. Any product described above is not intended to diagnose, treat, cure, or prevent any disease.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans," and similar expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could," generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company's control, including, but not limited to: the Company's ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company's business, operations, and the economy in general; and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of any new information, future events, or otherwise.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
SOURCE: Cosmos Health Inc.
View the original press release on ACCESS Newswire